Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Just as the rest of our world changed in the aftermath of the COVID-19 pandemic, the patient, healthcare provider, and drug company approach to medical information (MI) and pharmacovigilance (PV) at the local level is undergoing a major shift. For global pharmaceutical conglomerates, the prospect of navigating country safety activities and building a streamlined global system might seem overwhelmingly difficult without access to the needed resources. However, acquainting yourself with the current climate of PV and MI and the offerings of experienced local |
service providers might be the solution needed to alleviate this challenge. Currently, drug companies are facing major pressure to adapt to the following shifts and trends across the industry:
All drug companies are navigating different scenarios depending on their volume of product lifecycles and locations. Opting to invest in your PV and MI resources can yield major improvements for customer satisfaction and safety reporting mechanisms. Many companies have found success by outsourcing their PV and MI activities to an experienced organization that can provide creative, proven solutions. Investing in an outsourcing partnership designed to suit your needs can yield the following benefits:
Many of these benefits are a result of the wide spectrum of solutions offered by an experienced partner, including access to qualified persons for pharmacovigilance (QPPVs), a regulatory intelligence database (RID) with up-to-date PV legislation insight, human/artificial intelligence (AI) chat models to field MI requests, data insight enhancement, and more.
In a recent webinar hosted by IQVIA’s Local Affiliate Product Services (LAPS) team, Alisa Hummings, Senior Director and Head of Medical Information and Local AE Intake Services, and Simon Johns, Director, Medical Information and Marketed Product Safety, detail current trends across country activities and regulations as well as the benefits of utilizing technology to enhance your MI customer support model. To explore how to build out your PV and MI offerings, watch the complete webinar, or to read a full summary, download the comprehensive whitepaper.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Improve the performance of your clinical trials with the power of the IQVIA CORE.
Harness the power of global human expertise combined with automation, artificial intelligence (AI) and machine learning (ML) to design, build and execute end-to-end safety solutions.
End-to-end safety-focused local Qualified Person for Pharmacovigilance (QPPV) services and latest PV/MI technologies, ensure global consistency at a local country level and compliance with all local safety requirements. Expand your global pharmacovigilance, Medical Information, and safety capabilities with confidence - and without additional capital investment.